[1]王冠杰,王 鹏△.培美曲塞联合顺铂治疗非小细胞肺癌疗效及对患者细胞角质抗原21-1、磷酸化细胞外信号调节激酶水平的影响研究*[J].陕西医学杂志,2020,49(7):804-807.[doi:DOI:10.3969/j.issn.10007377.2020.07.009]
　WANG Guanjie,WANG Peng..Therapeutic effect of pemetrexed combined with cisplatin in treatment of non-small cell lung cancer and its influence on CYFRA21-1 and p-ERK levels[J].,2020,49(7):804-807.[doi:DOI:10.3969/j.issn.10007377.2020.07.009]
点击复制

培美曲塞联合顺铂治疗非小细胞肺癌疗效及对患者细胞角质抗原21-1、磷酸化细胞外信号调节激酶水平的影响研究*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年7期
页码:
804-807
栏目:
临床研究
出版日期:
2020-07-05

文章信息/Info

Title:
Therapeutic effect of pemetrexed combined with cisplatin in treatment of non-small cell lung cancer and its influence on CYFRA21-1 and p-ERK levels
作者:
王冠杰; 王 鹏△
西安市中心医院肿瘤科(西安710000)
Author(s):
WANG Guanjie; WANG Peng.
Department of Oncology,Xi'an Central Hospital(Xi'an 710000)
关键词:
培美曲塞;  顺铂;  非小细胞肺癌;  疗效;  细胞角质抗原21-1;  磷酸化细胞外信号调节激酶
Keywords:
Pemetrexed;  Cisplatin;  Non-small cell lung cancer;  Efficacy;  CYFRA21-1;  p-ERK
分类号:
R734.2
DOI:
DOI:10.3969/j.issn.10007377.2020.07.009
文献标志码:
A
摘要:
目的：研究了培美曲塞联合顺铂对非小细胞癌的治疗效果及对患者细胞角质抗原21-1(CYFRA21-1)、磷酸化细胞外信号调节激酶(p-ERK)水平的影响。方法:纳入收治的非小细胞肺癌(NSCLC)患者94例,随机分为对照组和观察组,各47例。对照组使用多西他赛联合顺铂进行化疗,观察组使用培美曲塞联合顺铂进行治疗。比较两组的近期疗效、安全性和1年生存率,比较两组以及不同病理分型治疗前后的CYFRA21-1、糖类抗原125(CA125)、p-ERK水平。结果: 对照组的治疗有效率明显低于观察组(P<0.05)。两组的1年生存率比较,差异无统计学意义(P>0.05)。治疗后,两组的CYFRA21-1、CA125、p-ERK水平均明显降低(P<0.05),其中对照组CYFRA21-1、CA125、p-ERK水平均明显高于观察组(P<0.05)。治疗后,NSCLC不同病理分型患者CYFRA21-1、CA125、p-ERK水平均明显下降(P<0.05),其中鳞癌患者CYFRA21-1、CA125、p-ERK水平均明显高于腺癌和鳞腺癌患者(P<0.05)。对照组恶心呕吐、肝功能损害和白细胞计数减少的发生率明显高于观察组(P<0.05)。结论:培美曲塞联合顺铂治疗NSCLC的疗效和安全性均较好, CYFRA21-1、CA125、p-ERK的水平经治疗后在不同病理分期患者中均明显下降,可作为评价NSCLC化疗效果的有效指标。
Abstract:
Objective:To study the therapeutic effect of pemetrexed combined with cisplatin in the treatment of non-small cell lung cancer(NSCLC)and its influence on CYFRA21-1 and p-ERK levels.Methods:94 NSCLC patients were randomly divided into control group and observation group,47 cases each.The control group was treated with docetaxel combined with cisplatin,and the observation group was treated with pemetrexed combined with cisplatin.The short-term efficacy,safety and 1-year survival rate of the two groups were compared,and the levels of CYFRA21-1,CA125 and p-ERK in the two groups and different pathological types were compared before and after treatment.Results:The effective rate of treatment in the control group was significantly lower than that in the observation group(P<0.05).There was no significant difference in the 1-year survival rate between the two groups(P>0.05).After treatment,the levels of CYFRA21-1,CA125 and p-ERK in the two groups were significantly reduced(P<0.05),and the levels of CYFRA21-1,CA125 and p-ERK in the control group were significantly higher than those in the observation group(P<0.05).After treatment,the levels of CYFRA21-1,CA125 and p-ERK in patients with different pathological types of NSCLC were decreased significantly(P<0.05),and the levels of CYFRA21-1,CA125 and p-ERK in patients with squamous cell carcinoma were significantly higher than those in patients with adenocarcinoma and adeno-squamous carcinoma(P<0.05).The incidence of nausea and vomiting,liver function impairment and leukocyte count decrease in the control group was significantly higher than that in the observation group(P<0.05).Conclusion:Pemetrexed combined with cisplatin has good efficacy and safety in the treatment of NSCLC.The levels of CYFRA21-1,CA125 and p-ERK after treatment are significantly reduced in patients with different pathological stages,which can be used as an effective index to evaluate the chemotherapy effect of NSCLC.

参考文献/References:

[1] 冯谢敏,赵 红,崔 洁,等.同步放化疗治疗局部晚期非小细胞肺癌疗效观察[J].陕西医学杂志,2016,45(9):1126-1128.
[2] 彭东旭,方晓娟,杜均详,等.培美曲塞联合顺铂化疗对晚期非小细胞肺癌患者血清肿瘤标志物的影响[J].临床肺科杂志,2016,21(7):1306-1309.
[3] 龚玉芳,刘 峰,杨志胤,等.新辅助化疗前后非小细胞肺癌患者血清CA125、CEA及CYFRA21-1的变化及预后分析[J].中国医药导报,2017,14(11):91-94.
[4] 林小峰,陈 龙.晚期非小细胞肺癌化疗现状及进展[J].广西医科大学学报,2019,36(5):850-855.
[5] 魏 瑜,杨 媚,张建清,等.含铂双药对比非铂单药二线治疗晚期非小细胞肺癌的系统评价[J].中华肿瘤防治杂志,2015,22(4):293-299.
[6] 王艳美,尚 华,刘丽梅,等.多西他赛动脉灌注联合三维适形放疗治疗晚期非小细胞肺癌临床研究[J].陕西医学杂志,2017,46(7):950-952.
[7] 杨 琳,仓顺东.吉西他滨联合顺铂方案与多西他赛联合顺铂方案治疗非小细胞肺癌的疗效比较[J].中国实用医刊,2019,46(8):79-82.
[8] 张雅军,徐 锋,韩纪昌,等.培美曲塞联合紫杉醇和顺铂治疗非小细胞肺癌的临床研究[J].中国临床药理学杂志,2016,32(15):1396-1399.
[9] 王晓东,景鹏宇,崔 凯,等.术前外周血中性粒细胞淋巴细胞比值对Ⅰ-Ⅲ期非小细胞肺癌患者预后的影响[J].陕西医学杂志,2019,48(12):1612-1615.
[10] 努尔兰?吐尔逊,周 永,韩文广,等.MSCT联合肿瘤标志物检查对中央型小细胞肺癌及非小细胞肺癌的鉴别诊断价值[J].临床放射学杂志,2016,35(5):59-64.
[11] 王 磊,李 飞,黄晓日,等.吉西他滨联合顺铂化疗对非小细胞肺癌患者肿瘤标志物的影响[J].中国肿瘤临床与康复,2017,8(4):30-32.
[12] 孙 斌,刘举珍,张飞飞.SPECT/CT断层融合显像联合血清CEA、CYFRA21-1在诊断非小细胞肺癌骨转移中的应用[J].国际放射医学核医学杂志,2018,42(3):212-217.
[13] 王晓燕,吴丽丽,曹雪珍,等.血清肿瘤标志物水平与晚期非小细胞肺癌患者靶向治疗有效性的相关分析[J].数理医药学杂志,2019,8(6):827-828.
[14] 刘 奕.肿瘤标志物CEA、NSE、SCC-Ag、CYFRA21-1与D-D联合检测在非小细胞肺癌早期诊断中的应用[J].泰山医学院学报,2019,12(3):203-206.
[15] 赵伟庆,季 枚,吴昌平.培美曲塞二钠联合卡铂治疗老年中晚期非小细胞肺癌的临床研究[J].中华全科医学,2008,6(11):1140-1141.

相似文献/References:

[1]杨 昕,刘 芳,杜 静,等.肺癌癌组织中过氧化物酶增殖体激活受体γ基因表达水平对培美曲塞化疗疗效的预测价值*[J].陕西医学杂志,2020,49(10):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
　YANG Xin,LIU Fang,DU Jing,et al.Predictive value of PPARγ gene expression level in lung cancer tissue for curative effect of pemetrexed chemotherapy[J].,2020,49(7):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
[2]林兴伟,戚新春.干扰TRIAP1表达增强口腔鳞状细胞癌细胞对顺铂敏感性实验研究[J].陕西医学杂志,2022,51(2):131.[doi:DOI:10.3969/j.issn.1000-7377.2022.02.001]
　LIN Xingwei,QI Xinchun.Interference with the expression of TRIAP1 enhances the sensitivity of oral squamous cell carcinoma cells to cisplatin[J].,2022,51(7):131.[doi:DOI:10.3969/j.issn.1000-7377.2022.02.001]
[3]高 娜,王崇宝.胸腺肽联合顺铂、培美曲塞二钠治疗晚期非小细胞肺癌临床疗效研究[J].陕西医学杂志,2022,51(11):1424.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.025]
　GAO Na,WANG Chongbao.Clinical efficacy of thymosin combined with cisplatin and pemetrexed disodium in treatment of advanced non-small cell lung cancer[J].,2022,51(7):1424.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.025]
[4]王松海,凡 瑾,陈 捷.红景天苷对Lewis 肺癌小鼠恶性胸腔积液的抑制作用及其对免疫功能的影响[J].陕西医学杂志,2024,(1):37.[doi:DOI:10.3969/j.issn.1000-7377.2024.01.008]
　WANG Songhai,FAN Jin,CHEN Jie.Inhibitory effect of SALidroside on malignant pleural effusion and its effect on immune function in mice with Lewis lung cancer[J].,2024,(7):37.[doi:DOI:10.3969/j.issn.1000-7377.2024.01.008]
[5]周家香,吴春芝,冯 芳,等.康莱特静脉注射联合顺铂灌注对晚期非小细胞肺癌患者免疫功能和肿瘤标志物的影响[J].陕西医学杂志,2024,(6):818.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.021]
　ZHOU Jiaxiang,WU Chunzhi,FENG Fang,et al.Effects of kanglaite intravenous injection combined with cisplatin perfusion on immune function and tumor markers in patients with advanced NSCLC[J].,2024,(7):818.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.021]
[6]冯敏娟,蔡东阁,李 虹.转录因子7-like 2在宫颈癌中表达水平及其与顺铂化疗敏感性关系研究[J].陕西医学杂志,2024,(10):1335.[doi:DOI:10.3969/j.issn.1000-7377.2024.10.008]
　FENG Minjuan,CAI Dongge,LI Hong.Expression level of transcription factor 7-like 2 in cervical cancer and its relationship with cisplatin chemotherapy sensitivity[J].,2024,(7):1335.[doi:DOI:10.3969/j.issn.1000-7377.2024.10.008]

备注/Memo

备注/Memo:
*陕西省重点研发计划项目(2018SF-267)
更新日期/Last Update: 2020-07-28